PubMed Health⌕ Search

Biomedical subjects

P Diem

Publications and source records attributed to P Diem.

At least 19 recordsLinked to original sources
PubMed2006

QTc interval and resting heart rate as long-term predictors of mortality in type 1 and type 2 diabetes mellitus: a 23-year follow-up.

AIMS/HYPOTHESIS: We evaluated the association of QT interval corrected for heart rate (QT(c)) and resting heart rate (rHR) with mortality (all-causes, cardiovascular, cardiac, and ischaemic heart disease) in subjects with type 1 and type 2 diabetes. METHODS: We followed 523 diabetic patients (221 with type 1 diabetes, 302 with type 2 diabetes) who were recruited between 1974 and 1977 in Switzerland for the WHO Multinational Study of Vascular Disease in Diabetes. Duration of follow-up was 22.6 +/- 0.6 years. Causes of death were obtained from death certificates, hospital records, post-mortem reports, and additional information given by treating physicians. RESULTS: In subjects with type 1 diabetes QT(c), but not rHR, was associated with an increased risk of: (1) all-cause mortality (hazard ratio [HR] 1.10 per 10 ms increase in QT(c), 95% CI 1.02-1.20, p = 0.011); (2) mortality due to cardiovascular (HR 1.15, 1.02-1.31, p = 0.024); and (3) mortality due to cardiac disease (HR 1.19, 1.03-1.36, p = 0.016). Findings for subjects with type 2 diabetes were different: rHR, but not QT(c) was associated with mortality due to: (1) all causes (HR 1.31 per 10 beats per min, 95% CI 1.15-1.50, p < 0.001); (2) cardiovascular disease (HR 1.43, 1.18-1.73, p < 0.001); (3) cardiac disease (HR 1.45, 1.19-1.76, p < 0.001); and (4) ischaemic heart disease (HR 1.52, 1.21-1.90, p < 0.001). Effect modification of QT(c) by type 1 and rHR by type 2 diabetes was statistically significant (p < 0.05 for all terms of interaction). CONCLUSIONS/INTERPRETATION: QT(c) is associated with long-term mortality in subjects with type 1 diabetes, whereas rHR is related to increased mortality risk in subjects with type 2 diabetes.

Adult↗
PubMed2006

[Long-term follow up after antithyroid drug treatment in Graves' disease].

BACKGROUND AND OBJECTIVE: In Europe antithyroid drug (ATD) therapy is the preferred initial treatment for patients with a first episode of Graves' disease. Results of long-term recurrence rates following ATD therapy are conflicting. The main goal was to assess long-term recurrence rate after ATD treatment. Secondarily we tried to verify chemical and clinical findings (thyrotropin receptor antibodies (TRAb), duration of primary treatment, age and goitre size) as predictive factors. PATIENTS AND METHODS: Records of 94 patients with a first episode of Graves' disease (1990-1995) treated by ATD were retrospectively analyzed. 18 patients were lost for follow up investigations, the remaining 76 (65 women, 11 men, age 16-76 years) patients were followed for 99 (+/- 22) months (mean +/- SD). To verify the predictive factors a logistic regression analysis was done. RESULTS: Among the 76 patients 16 underwent near-total resection (n = 5) or radioiodine therapy (n = 11) after initial ATD treatment. Sixty patients were treated during 19 +/- 16 months (mean +/- SD) with ATDs and were euthyroid when treatment was stopped. Thirteen of the 60 patients (21.7%) remained in remission after discontinuation of ATD therapy, in 42 patients (70%) hyperthyroidism recurred, in four patients (6.7%) ATD could not be stopped, one patient (1.7%) had a persistent hypothyroidism after discontinuation of ATD. Relapse rate was inversely correlated with duration of primary ATD treatment (p < 0.05), but not with TRAb titer at the time of diagnosis nor at the time of ATD discontinuation. Also, no correlation could be noticed with goitre size at the time of diagnosis. An inverse correlation of the age at the time of diagnosis with relapse rate was of only borderline significance (p = 0.055). CONCLUSIONS: Initial successful treatment with ATD is followed by a high recurrence rate in our population. Two possible negative predictors of relapse are short duration of primary ATD treatment and young age at the time of diagnosis. TRAb titer at the time of diagnosis or at the time of ATD discontinuation and goitre size seem to have no influence on the outcome.

Adolescent↗
PubMed2006

Apolipoprotein B as a long-term predictor of mortality in type 1 diabetes mellitus: a 15-year follow up.

OBJECTIVES: To evaluate the association of apolipoprotein B (apo B) with mortality due to all causes, to cardiac disease and to ischaemic heart disease (IHD) in subjects with type 1 diabetes mellitus. SUBJECTS: 165 subjects with type 1 diabetes included in the Swiss Cohort of the WHO Multinational Study of Vascular Disease in Diabetes were followed for 14.7+/-0.45 years. METHODS: Causes of death were obtained from death certificates, hospital records and postmortem reports. Using a parametric proportional hazards model the association of apo B with mortality rates was assessed by time-to-event analysis, including the absolute cumulative mortality risk over time for various apo B levels at baseline. RESULTS: Apo B was positively associated with all-cause mortality [hazard ratio (HR) 2.65 per g L-1 increase of apo B, 95% CI: 1.11-6.36, P=0.029], cardiac mortality (HR 11.64, 1.03-131.11, P=0.047) and IHD mortality (HR 9.36, 1.26-69.66, P=0.029). An apo B>or=0.96 g L-1 translated into a duplication of overall mortality hazard (HR 1.93, 1.00-3.72, P=0.050), and a sevenfold increase of mortality because of cardiac disease or IHD (HR 7.44, 1.44-38.42, P=0.017 and HR 7.38, 0.78-69.82, P=0.081). A baseline apo B of 1.5 g L-1 predicted an absolute cumulative risk to die over the next 10 years of 12.1% (5.2-31.7) for male and of 10.4% (4.7-26.1) for female subjects whereas risks were 6.3% (1.8-21.4) and 5.4% (0.8-15.8) for an apo B of 0.8 g L-1. CONCLUSION: Apo B is consistently associated with an increased mortality in type 1 diabetes.

Apolipoproteins B↗
PubMed2005

Efficacy of drug eluting stents in patients with and without diabetes mellitus: indirect comparison of controlled trials.

OBJECTIVE: To examine whether polymer based coronary stents eluting sirolimus or paclitaxel are equally effective in patients with and without diabetes. METHODS: Systematic review and meta-analysis by indirect comparison of randomised controlled trials comparing stents eluting sirolimus or paclitaxel with conventional bare metal stents. The overall study population and patients with and without diabetes were analysed separately by using the ratio of incidence rate ratios (RIRR). RESULTS: The analysis was based on 10 trials (six with sirolimus, four with paclitaxel), 4513 patients (1146 patients with diabetes), 5755 years of follow up, and 2464 events. In patients without diabetes sirolimus eluting stents were superior to paclitaxel eluting stents with respect to in-stent (RIRR 0.21, 95% confidence interval (CI) 0.10 to 0.48, p < 0.001) and in-segment restenosis (RIRR 0.47, 95% CI 0.24 to 0.92, p = 0.027), target lesion revascularisation (RIRR 0.54, 95% CI 0.30 to 0.99, p = 0.045), and major adverse cardiac events (RIRR 0.46, 95% CI 0.26 to 0.83, p = 0.010). In patients with diabetes the two drug eluting stents did not differ significantly in any of these end points. Meta-regression analysis showed a significant difference between patients with and without diabetes (tests for interaction for in-stent and in-segment restenosis, p = 0.036 and p = 0.016). CONCLUSION: Indirect evidence indicates that sirolimus eluting stents are superior to paclitaxel eluting stents in patients without diabetes but not in patients with diabetes.

Blood Vessel Prosthesis↗
PubMed2005

[Endogenous hypercortisolism and immunologically-mediated disease: three cases].

HISTORY AND CLINICAL FINDINGS: We report three women with hypercortisolism presenting with symptoms and signs of Cushing's syndrome. In two of the patients, initial symptoms of hypercortisolism were associated with spontaneous amelioration of previously known atopic dermatitis and psoriasis, respectively. DIAGNOSTIC PROCEDURES: Diagnosis was established by demonstrating both lack of responsiveness to dexamethasone (1mg) suppression test and increased 24-hour urine cortisol secretion. One patient had a low serum ACTH level indicating Cushing's syndrome of adrenal origin. In the other two patients hypercortisolism proved to be ACTH-dependent, the source being the pituitary, as demonstrated by CRH stimulation test (elevation of ACTH and cortisol by 35 % and 20 %, respectively) and sampling of the petrosus sinus. In both patients imaging confirmed the presence of a pituitary adenoma. TREATMENT AND COURSE: All three patients underwent successful surgery: the first patient had an adrenalectomy, the other two transseptal transsphenoidal hypophysectomy. As symptoms and signs of hypercortisolism improved, the previously quiescent signs of atopic dermatitis and psoriasis recurred and one patient developed Graves' disease. CONCLUSIONS: Following successful treatment of endogenous hypercortisolism, symptoms of unrelated immunologically mediated conditions, especially autoimmune thyroiditis, may occasionally appear. Furthermore, the clinical course of coexisting immunologically mediated diseases may help to diagnose Cushing's syndrome and to monitor the patients after surgical treatment.

Adult↗
PubMed2005

Treatment outcomes and mortality of 94 patients with acromegaly.

BACKGROUND: Due to new therapeutic modalities and modified therapeutic goals outcome of patients with acromegaly may change over time and differ by centre. We analysed treatment outcomes and mortality of our patients with acromegaly seen between 1971 and 2003. METHOD: The cohort consisted of 94 patients who had been followed for 0.3-31 years (mean 10.6 years). Remission criteria were a normalized IGF-I concentration, a nadir GH level during oral glucose load of <1.0 microg/l and a random GH value of <2.5 microg/l. FINDINGS: Transsphenoidal surgery achieved remission in 80% of patients with micro-adenomas (<1 cm), 65% with meso-adenomas (> or = 1 cm to <2 cm) and 27% with macro-adenomas (> or = 2 cm). Patients with meso-adenomas operated on after 1995 tended to have a better outcome compared to those operated on before 1995 (Remission in 83% vs. 38%). Radiotherapy resulted in disease control in 22 of 47 patients (47%). Intramuscular depot formulation of octreotide (Sandostatin LAR) led to disease control in 17 of 26 patients (65%). After multimodal therapy persistent acromegalic activity remained in 18% of the patients; only one of them had an adenoma of <2 cm. The standardized mortality ratio was 1.30 (95% CI 0.52-2.67) for patients in remission and 1.38 (95% CI 0.51-3.00) for patients with persistent acromegalic activity. CONCLUSIONS. Most patients with adenomas of <2 cm can be expected to achieve remission by transsphenoidal surgery alone. Furthermore, virtually all patients with adenomas of <2 cm and more than 80% of patients with adenomas of > or = 2 cm can be expected to achieve remission by adjuvant treatment. Aggressive multimodal therapy is critical in the management of acromegaly reducing mortality risk close to that of the general population.

Acromegaly↗
PubMed2005

Sitosterolaemia in Switzerland: molecular genetics links the US Amish-Mennonites to their European roots.

Sitosterolaemia is a rare autosomal recessive disease characterized by increased intestinal absorption of plant sterols, decreased hepatic excretion into bile and elevated concentrations in plasma phytosterols. Homozygous or compound heterozygous loss of function mutations in either of the ATP-binding cassette (ABC) proteins ABCG5 and ABCG8 explain the increased absorption of plant sterols. Here we report a Swiss index patient with sitosterolaemia, who presented with the classical symptoms of xanthomas, but also had mitral and aortic valvular heart disease. Her management over the last 20 years included a novel therapeutic approach of high-dose cholesterol feeding that was semi-effective. Mutational and extended haplotype analyses showed that our patient shared this haplotype with that of the Amish-Mennonite sitosterolaemia patients, indicating they are related ancestrally.

Adult↗
PubMed2004

Quality of life and coping behaviour in Type 1 diabetes mellitus: relationship with metabolic control.

Uncovering factors possibly leading to insufficient metabolic control in Type 1 diabetes, both on the part of the patient or the treating physician, is of considerable relevance. The present long-term study investigated the relevance of patient-related vs education-related factors for the success in achieving acceptable glycaemic control. Adolescents or young adults with Type 1 diabetes mellitus (n= 26, mean age= 22+/-2 yr, diabetes duration= 11+/-5 yr) were followed during 36+/-5 months. All patients were treated by the same diabetologist. At the beginning of the study coping behaviour, quality of life and evaluation of emotional status were assessed. Changes in HbA1c were used as a parameter of glycaemic control. At follow-up there was a significant decrease in HbA1c of 0.4% (p<0.01). However, this was not in statistically significant correlation with age, gender, aspects of quality of life or coping behaviour. Therefore, glycaemic control and/or improvement of glycaemic control in adolescents or young adults with Type 1 diabetes mellitus seems to be primarily related to other factors, eg continuous education provided in a stable setting.

Adaptation, Psychological↗
PubMed2003

Effects of alcohol consumption on mortality in patients with Type 2 diabetes mellitus.

AIMS/HYPOTHESIS: Moderate alcohol intake has been associated with increased life expectancy due to reduced mortality from cardiovascular disease. We prospectively examined the effects of alcohol consumption on mortality in Type 2 diabetic patients in Switzerland. METHODS: A total of 287 patients with Type 2 diabetes mellitus (125 women, 162 men), recruited in Switzerland for the WHO Multinational Study of Vascular Disease in Diabetes, were included in this study. After a follow-up period of 12.6+/-0.6 years (means +/- SD), mortality from CHD and from all causes was assessed. RESULTS: During the follow-up, 70 deaths occurred (21 from CHD, 49 from other causes). Compared with non-drinkers, alcohol consumers who drank alcohol 1 to 15 g, 16 to 30 g and 30 g or more per day had the following risk rates of death from CHD: 0.87 (95% CI: 0.25 to 2.51, NS), 0.00 (95% CI: 0.00 to 0.92, p less than 0.05) and 0.37 (95% CI, 0.01 to 2.42, NS), respectively. The corresponding risk rates of death from all causes were 1.27 (95% CI: 0.68 to 2.28, NS), 0.36 (95% CI: 0.09 to 0.99, p less than 0.05) and 1.66 (95% CI: 0.76 to 3.33, NS). CONCLUSIONS/INTERPRETATION: In Swiss Type 2 diabetic patients moderate alcohol consumption of 16 to 30 g per day was associated with reduced mortality from CHD and from all causes. Alcohol intake above 30 g per day was associated with a tendency towards increased all-cause mortality.

Adult↗
PubMed2003

Diagnosis of diabetic autonomic neuropathy: a multivariate approach.

AIM/HYPOTHESIS: In the diagnosis of diabetic autonomic neuropathy (DAN) various autonomic tests are used. We took a novel statistical approach to find a combination of autonomic tests that best separates normal controls from patients with DAN. METHODS: Twenty-four patients with Type-1 diabetes mellitus considered as having mild to moderate DAN as well as 10 normal, nondiabetic control subjects were analysed, searching for a test or a combination of tests that would optimally discriminate Type-1 diabetes mellitus from controls. Variations of heart rate during deep breathing (deltaR6) and during a Valsalva manoeuvre (VR), the number of reactive sweat glands on the foot (testing sympathetic sudomotor function), and the response of human pancreatic polypeptide to hypoglycaemia [ln(deltahPP+1)] were evaluated. RESULTS: Respective values for respective sensitivity and specificity values were: deltaR6, 96 and 70%; VR, 96 and 60%; sweat gland function, 71 and 90%; and ln(deltahPP+1), 71 and 90%. In a multivariate analysis approach a single discriminant function separating patients with Type-1 diabetes mellitus from nondiabetic controls was generated [Logit P=288.5-[14.7 deltaR6]-[26.6 ln(deltahPP+1)]]. This function allowed complete separation of patients with Type-1 diabetes mellitus from normal controls. CONCLUSION/INTERPRETATION: We conclude that the combined determination of deltaR6 and of ln (deltahPP+1) optimally separates subjects with parasympathetic impairment from normal subjects. In addition, this combination of tests may serve as a sensitive method for the assessment of DAN.

Adult↗
PubMed2002

[The paradox of TSH elevation in Sheehan's syndrome].

HISTORY AND CLINICAL FINDINGS: A 59-year-old woman was examined because of weight gain, increasing fatigue and secondary amenorrhoea, which occurred after a complicated delivery at age 18. The finding of an increased TSH concentration was initially considered as primary hypothyroidism and substitution therapy was commenced. Because of the concomitant secondary amenorrhoea the patient was referred for additional endocrinological investigations. INVESTIGATIONS: Biochemical analysis confirmed the increase in TSH concentrations, and revealed a gonadotropin deficiency, a decrease in IGF-I concentration and a free urinary cortisol concentration at the lower end of the normal range. Dynamic testing of pituitary function (insulin tolerance test) confirmed a severe growth hormone deficiency and partial secondary adrenal insufficiency. An MRI study of the pituitary showed an empty sella with some remaining pituitary tissue at the bottom of the sella. DIAGNOSIS, TREATMENT AND CLINICAL COURSE: The laboratory findings of pituitary insufficiency with an empty sella on MRI scan suggested Sheehan's syndrome despite an increase in thyrotropin level. Pituitary replacement therapy was started with hydrocortone, combined estrogens and progesterone in addition to levothyroxin, which considerably improved clinical symptoms. CONCLUSION: A history of secondary amenorrhoea after a complicated delivery including significant bleeding or septic complications suggest Sheehan's syndrome, which can result in partial or complete panhypopituitarism. In such circumstances the pituitary hormone levels are usually reduced. TSH concentrations, however, may be increased.

Amenorrhea↗
PubMed2002

[Hypophyseal incidentaloma in a patient with autosomal dominant polycystic kidney disease].

The prevalence of incidentally discovered lesions within the pituitary (pituitary incidentalomas) is about 10%. The most common form of sellar mass are clinically nonfunctioning adenomas (less than 10 mm); functioning adenomas, however, are rare. Incidentally discovered pituitary microadenomas causing growth hormone hypersecretion are uncommon. In addition, the association of autosomal dominant polycystic kidney disease with acromegaly is exceptional and has not yet been reported to our knowledge.

Acromegaly↗
PubMed2002

[Treatment of hypertension in type 2 diabetes mellitus--2002 update].

Arterial hypertension and diabetes are potent independent risk factors for cardiovascular, cerebral, renal and peripheral (atherosclerotic) vascular disease. The prevalence of hypertension in diabetic individuals is approximately twice that in the non-diabetic population. Diabetic individuals with hypertension have a greater risk of macrovascular and microvascular disease than normotensive diabetic individuals. Hypertension is a major contributor to morbidity and mortality in diabetes, and should be recognized and treated early. Type 2 diabetes and hypertension share certain risk factors such as overweight, visceral obesity, and possibly insulin resistance. Life-style modifications (weight reduction, exercise, limitation of daily alcohol intake, stop smoking) are the foundation of hypertension and diabetes management as the definitive treatment or adjunctive to pharmacological therapy. Additional pharmacological therapy should be initiated when life-style modifications are unsuccessful or hypertension is too severe at the time of diagnosis. All classes of antihypertensive drugs are effective in controlling blood pressure in diabetic patients. For single-agent therapy, ACE-inhibitors, angiotensin receptor blocker, beta-blockers, and diuretics can be recommended. Because of concerns about the lower effectiveness of calcium channel blockers in decreasing coronary events and heart failure and in reducing progression of renal disease in diabetes, it is recommended to use these agents as second-line drugs for patients who cannot tolerate the other preferred classes or who require additional agents to achieve the target blood pressure. The choice depends on the patients specific treatment indications since each of these drugs have potential advantages and disadvantages. In patients with microalbuminuria or clinical nephropathy, both ACE-inhibitors and angiotensin receptor blockers are considered first line therapy for the prevention of and progression of nephropathy. Since treatment is usually life-long, cost effectiveness should be included in treatment evaluation.

Antihypertensive Agents↗
PubMed2002

[Systematic aspects and therapy of diabetic neuropathy].

Diabetic neuropathy (DN) is an important complication contributing to high morbidity and morbidity of diabetic subjects. Primarily, interventional strategies aim at normalization hyperglycemia (to prevent development and progression of DN), at early diagnosis and at prevention of ulcers and amputations. In addition, an increasing number of pharmaceutical agents is used to symptomatically treat dysesthesia and pain associated with DN. During recent years attempts have been made to pharmacologically treat DN by acting on underlying patho-physiological mechanisms (e.g. sorbitol pathway, non-enzymatic glycation, microvascular abnormalities). So far, these strategies have not changed clinical praxis. This review will give a systematic overview of DN and summarize current pharmacological options to symptomatically treat dysesthesia and pain associated with DN.

Combined Modality Therapy↗
PubMed2001

[Calculating the basal metabolic rate and severe and morbid obesity].

BACKGROUND AND OBJECTIVE: The aim of this study was to evaluate the currently available predictive equations for basal metabolic rate (BMR) in subjects with obesity class II and III, and to assess the contribution by the components of a two-compartment model of body composition, namely the lean body mass (LBM) and the fat mass (FM) to the prediction. A second objective was to examine the reliability of the Harris Benedict equation in obese subjects, especially with a weight > or = 120 kg. PATIENTS AND METHODS: In 43 patients (age range 18 to 61 years, 5 men, 38 women) with obesity class II and III (body mass index, BMI, mean +/- SD 45.6 kg/m2 +/- 5.4 kg/m2, range 37.1-58.6 kg/m2) basal metabolic rate BMR was determined using indirect calorimetry (Deltatrac MBM, Datex, Instrumentarium Corp., Helsinki, Finnland) and the components of body composition were determined using the bioelectrical-impedance-analysis (BIA) method (BIA, Akern-Gerät, RJL Systems, Detroit). Calculated BMR was compared with measured BMR. RESULTS: The best fitting equations for predicting BMR in these 43 severe und morbidly obese subjects were the Harris-Benedict (ratio calculated BMR to measured, BMR mean +/- SD%; correlation coefficient r = 101 +/- 12.9; 0.69), the Jensen (101.5 +/- 12.3; 0.74), the Nelson (99.3 +/- 11.4; 0.76) and the Cunningham equation (98.9 +/- 11.7; 0.74). The predictive value of the original Harris-Benedict equation was slightly different from modified Harris-Benedict equation, which was recalculated by Roza et al. (101.1 +/- 12.9; 0.69 vs. 99.7 +/- 12.8; 0.69). In the group of the 22 subjects with a body weight > or = 120 kg ratio of estimated values for BMR using original Harris-Benedict equation to measured BMR was 102.2 +/- 15.4% (mean +/- SD%, r = 0.61), respectively 93.2 +/- 14.5% (r = 0.50) when weight was set at 120 kg due to current recommendations. The ratio calculated BMR/measured BMR according to the Nelson equation in this subgroup was 101.0 (12.1/0.74). CONCLUSION: In patients with obesity class II and III the equation of Harris-Benedict predicted the average BMR with acceptable precision for clinical use and was better fitting than most of the currently available predictive equations for basal metabolic rate (BMR). However, the recalculated version (by Roza et al.) was more accurate and should therefore be used instead of the original equation: BMR (men) = 88.362 + 4.799 x (length) + 13.397 x (weight) - 5.677 x (age); BMR (women) = 447.593 + 3.098 x (length) + 9.247 x (weight) - 4.330 x (age). The Nelson equation, including not only LBM but FM as additional predictor, was the best predicting equation ([108 LBM + 16.9 FM]0.239). Harris-Benedict equation had sufficient precision also in extreme obese subjects with a body weight > or = 120 kg, so there is no need for adaptation.

Adolescent↗
PubMed2001

Graves' ophthalmopathy: natural history and treatment outcomes.

BACKGROUND: The pathogenesis of Graves' ophthalmopathy has not been yet clarified, and from a therapeutic standpoint Graves' ophthalmopathy remains an enigma. The natural course and effects of different treatment regimens are poorly documented. RESULTS: The mean observation period was 3.23 years (1-8.9 years) for all 196 patients, and 2.85 years (1-8.9 years) for the 81 patients with Graves' ophthalmopathy. The gender distribution was 77% female and 23% male in patients with Graves' disease and ophthalmopathy, and 81% female and 19% male in those patients without ophthalmopathy (p = 0.57). Seventy per cent of the patients developed Graves' ophthalmopathy within 12 months before or after the onset of the hyperthyroidism. Among the 81 patients with ophthalmopathy 53 (65%) received no therapy or only local protective agents. Twenty-five of these patients improved substantially, 26 did not change, and 2 deteriorated progressively. These results were independent of the severity of the EO (p = 0.42). Among the 11 patients initially treated with systemic corticosteroids 7 improved, 3 did not change, and 1 worsened. Five patients received initially orbital irradiation. Three improved and 2 did not change after radiotherapy. Orbital decompression was performed in 3 patients. Nine patients received a combination treatment. CONCLUSION: In conclusion, our study of a relatively large patient sample revealed the known epidemiological facts regarding Graves' disease and endocrine ophthalmopathy. The majority of patients needed no therapy or only local protective agents, and 47% improved spontaneously. Systemic corticosteroids and orbital irradiation appear to be equally effective as initial treatment in patients with more severe forms of Graves' ophthalmopathy.

Adult↗
PubMed2001

Postexercise fat intake repletes intramyocellular lipids but no faster in trained than in sedentary subjects.

The hypotheses that postexercise replenishment of intramyocellular lipids (IMCL) is enhanced by endurance training and that it depends on fat intake were tested. Trained and untrained subjects exercised on a treadmill for 2 h at 50% peak oxygen consumption, reducing IMCL by 26-22%. During recovery, they were fed 55% (high fat) or 15% (low fat) lipid energy diets. Muscle substrate stores were estimated by (1)H (IMCL)- and (13)C (glycogen)-magnetic resonance spectroscopy in tibialis anterior muscle before and after exercise. Resting IMCL content was 71% higher in trained than untrained subjects and correlated significantly with glycogen content. Both correlated positively with indexes of insulin sensitivity. After 30 h on the high-fat diet, IMCL concentration was 30-45% higher than preexercise, whereas it remained 5-17% lower on the low-fat diet. Training status had no significant influence on IMCL replenishment. Glycogen was restored within a day with both diets. We conclude that fat intake postexercise strongly promotes IMCL repletion independently of training status. Furthermore, replenishment of IMCL can be completed within a day when fat intake is sufficient.

Adult↗